NeoLight

Executive Summary

NeoLight is a privately held medical device company dedicated to improving neonatal care through innovative technologies. Founded in 2014 and headquartered in Scottsdale, Arizona, the company has developed a portfolio of devices addressing critical needs in newborn medicine. Its flagship product, the Skylife Neonatal Phototherapy System, is designed for the effective treatment of infant jaundice, a common condition affecting newborns. Beyond phototherapy, NeoLight’s pipeline includes devices for brain monitoring, ocular screening, and supporting non-nutritive sucking development, positioning the company as a comprehensive solution provider in the neonatal intensive care unit (NICU) setting. By focusing on evidence-based, user-friendly devices, NeoLight aims to improve clinical outcomes and reduce the burden on healthcare providers. The company operates in the ophthalmology and medical device sectors, targeting a market with strong demand for specialized neonatal technologies. While NeoLight has not disclosed its total funding or valuation, its commercial-stage product (Skylife) indicates revenue generation and market traction. Going forward, NeoLight could benefit from expanding its product line, securing FDA clearances for new devices, and forming partnerships with hospital systems and distributors. The neonatal care market is poised for growth, driven by rising preterm birth rates and increasing awareness of early intervention. NeoLight’s ability to innovate and bring cost-effective solutions to market will be key to its success.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for NeoLight Brain Monitoring Device70% success
• Q2 2026Commercial Partnership with Major NICU Distributor for Skylife60% success
• Q4 2026Publication of Clinical Study on Ocular Screening Device Efficacy80% success